Shanghai MicuRx Pharmaceutical Co. Ltd. A
Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resi… Read more
Market Cap & Net Worth: Shanghai MicuRx Pharmaceutical Co. Ltd. A (688373)
Shanghai MicuRx Pharmaceutical Co. Ltd. A (SHG:688373) has a market capitalization of $527.18 Million (CN¥3.87 Billion) as of March 19, 2026. Listed on the SHG stock exchange, this China-based company holds position #12549 globally and #3122 in its home market, demonstrating a 4.42% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai MicuRx Pharmaceutical Co. Ltd. A's stock price CN¥5.90 by its total outstanding shares 655605491 (655.61 Million).
Shanghai MicuRx Pharmaceutical Co. Ltd. A Market Cap History: 2022 to 2026
Shanghai MicuRx Pharmaceutical Co. Ltd. A's market capitalization history from 2022 to 2026. Data shows change from $791.67 Million to $527.18 Million (-15.61% CAGR).
Shanghai MicuRx Pharmaceutical Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai MicuRx Pharmaceutical Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.39x
Shanghai MicuRx Pharmaceutical Co. Ltd. A's market cap is 3.39 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $791.67 Million | $48.21 Million | -$220.30 Million | 16.42x | N/A |
| 2023 | $583.48 Million | $90.78 Million | -$421.12 Million | 6.43x | N/A |
| 2024 | $441.40 Million | $130.27 Million | -$440.72 Million | 3.39x | N/A |
Competitor Companies of 688373 by Market Capitalization
Companies near Shanghai MicuRx Pharmaceutical Co. Ltd. A in the global market cap rankings as of March 19, 2026.
Key companies related to Shanghai MicuRx Pharmaceutical Co. Ltd. A by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Shanghai MicuRx Pharmaceutical Co. Ltd. A Historical Marketcap From 2022 to 2026
Between 2022 and today, Shanghai MicuRx Pharmaceutical Co. Ltd. A's market cap moved from $791.67 Million to $ 527.18 Million, with a yearly change of -15.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥527.18 Million | -2.32% |
| 2025 | CN¥539.69 Million | +22.27% |
| 2024 | CN¥441.40 Million | -24.35% |
| 2023 | CN¥583.48 Million | -26.30% |
| 2022 | CN¥791.67 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Shanghai MicuRx Pharmaceutical Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $527.18 Million USD |
| MoneyControl | $527.18 Million USD |
| MarketWatch | $527.18 Million USD |
| marketcap.company | $527.18 Million USD |
| Reuters | $527.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.